22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
It’s no secret that California is typically viewed as the most employee-friendly state in the count...
Read More >
Effective February 10, 2020, the top ten members of an out-of-state limited liability company (“LLC...
Read More >
The construction contract calls for International Building Code-compliant lumber. The insured doesn’...
Read More >
Over the summer, we wrote about why health care companies may want to consider buying assets out of ...
Read More >
The Workers’ Compensation Appeals Board (WCAB) issued a unanimous en banc decision on November 14, ...
Read More >
The number of workers aged 55 and over is increasing, while the number of workers under the age of 2...
Read More >